Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Medibank Private (MPL.AX)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (A$)	Price Target (A$)	Rating
2022-02-16	3.22	3.50	Neutral
2022-02-28	3.18	3.25	Neutral
2022-07-05	3.29	3.35	Neutral
2022-07-26	3.44	3.90	Buy
2022-08-18	3.55	4.00	Buy
2022-10-26	2.87	3.70	Buy
2023-05-26	3.57	4.00	Buy
2023-07-03	3.49	4.20	Buy
2023-10-27	3.39	4.30	Buy
2024-02-22	3.65	4.20	Buy
2024-08-22	3.83	4.30	Buy
2025-02-27	4.42	4.90	Buy
2025-04-02	4.60	5.10	Buy

Disclosures

UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.